Nebivolol v lechenii patsientov s khronicheskoy serdechnoy nedostatochnost'yu
- Authors: Shalaev S.V1, Kremneva L.V1, Abaturova O.V1
-
Affiliations:
- Issue: No 13 (2015)
- Pages: 84-87
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288120
- ID: 288120
Cite item
Open Access
Access granted
Abstract
Cardiovascular diseases occupy a leading position in the structure of adult mortality in the Russian Federation. Chronic heart failure (CHF) is the outcome of many cardiovascular diseases. The basis of the treatment of patients with chronic heart failure includes β-adrenoblockers. Nebivolol is one of the representatives of this group recommended for the treatment of patients with CHF. Treatment with nebivolol leads to the significant reduction in the combined risk of death and hospitalization for cardiovascular disease. In patients with ischemic etiology of CHF, nebivolol significantly reduces the incidence of acute ischemic complications.
Keywords
Full Text
References
- Cohn J.N., Bristow M.R., Chien K.R. Report of the National Heart, Lung and Blood Institute Special Emphasis Panel on Heart Failure Research. Cirailation. 1997;95:766-70.
- Heidlan U.E., Strauer B.E. Left ventricular muscle mass and elevated heart are associated with coronary plaque disruption. Circulation. 2001:1477-82.
- Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J.V., Waagstein F., Wedel H., Wessman P., WikstrandJ. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. CORONA Study Group. Eur. J. Heart Fail. 2005;7(6):1059-69.
- Hasenfuss G., Holubarsch C., Hermann H.P., Astheimer K., Pieske B., Just H. Influence of the force-frequency relationship on haemody-namics and left ventricular function in patients with nonfailing hearts and in patients with dilated cardiomyopathy. Eur. Heart J. 1994:
- Bohm M., Schwinger R.H., Koch A., Schmidt U., Morano I., Eissner H.J., Uberfuhr P., Reichart B., Erdmann E. The failing humen heart is unable to use the Frank-Starling mechanism. Circ. Res. 1994;74:959-69.
- Green S.J., Vaduganathan M., Wilcox J.E., Harinstein M.E., Maggioni A.P., Subacius H., Zannad F., Konstam M.A., Chioncel O., Yancy C.W., Swedberg K., Butler J., Bonow R.O., Gheorghiade M. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm. Heart Fail. 2013;6:488-506.
- Лугай М.И., Лысенко А.Ф., Анализ медикаментозной терапии ишемической болезни сердца в Украине: результаты исследования PULSAR. Укр. кардиол. журн. 2010;3:36-43.
- Rienstra M., Damman K., Mulder B.A., Van Gelder I.C., McMurray J.J., Van Veldhuisen D.J. Beta-blockers and outcome in heart failure and atrial fibrillation. A meta-analysis. JACC Heart Fail. 2013;1(1):21-8.
- Flather M.D., Shibata M.C., Coats A.J.S., Van Veldhuisen D.J., Parkhomenko A., Borbola J., Cohen-SolalA.,DumitrascuD.,FerrariR.,LechatP., Soler-Soler J., Tavazzi L., Spinarova L., Toman J., Böhm M., Anker S.D., Thompson S.G., Poole-Wilson P.A. Randomized trial to determine the effect nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J. 2005:26:215-25.
- Ambrosio G., Flather M.D., Bohm M. B-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart. 2011;97(3):209-14.
Supplementary files
